bluebird bio (BLUE) Q2 2024 earnings summary

Executive summary

• Achieved significant progress with three ongoing commercial gene therapy launches (ZYNTEGLO, SKYSONA, LYFGENIA), supported by a robust network of over 70 qualified treatment centers, with all product revenue from U.S. sales for the period ended June 30, 2024.

• Demonstrated strong patient and provider demand, with 27 patient starts in 2024 and over 40 additional patients scheduled for cell collection by year-end; expect approximately 85 patient starts across the portfolio in 2024.

• Underwent a major restructuring in September 2024, reducing workforce by 25% to optimize cost structure.

• Restated prior period financials due to lease accounting errors, resulting in increased legal and accounting costs and a material weakness in internal controls.

• Secured broad access and reimbursement, including Medicaid and commercial payers, with no ultimate denials for ZYNTEGLO and SKYSONA.

Financial highlights

• Q2 2024 revenue was $16.1 million, up from $6.8 million in Q2 2023; six-month product revenue was $34.7 million, up from $9.1 million year-over-year.

• Net loss for Q2 2024 was $81.4 million, compared to $62.8 million in Q2 2023; six-month net loss was $151.2 million.

• Gross margin for Q2 2024 was negative $12.8 million, reflecting high cost of product revenue ($28.9 million) relative to sales.

• As of June 30, 2024, cash, cash equivalents, and restricted cash totaled $193.4 million, including $49.2 million in restricted cash.

• Accumulated deficit reached $4.4 billion as of June 30, 2024.

Outlook and guidance

• On track for approximately 85 patient starts across the portfolio in 2024, with acceleration expected in the second half of the year.

• Revenue recognition expected to lag cell collection by about two quarters due to manufacturing and scheduling timelines.

• Expects gross-to-net discounts of 20%-25% across all three products in 2024, with fluctuations based on product, payer mix, and outcomes-based agreements.

• Cash runway projected into Q2 2025, or Q1 2025 factoring in loan covenants and minimum cash requirements.

• Management acknowledges substantial doubt about ability to continue as a going concern for 12 months without additional funding.